Joint disease, the hallmark of haemophilia: What issues and challenges remain despite the development of effective therapies?

Thierry Lambert, Günter Auerswald, Gary Benson, Ulla Hedner, Victor Jiménez-Yuste, Rolf Ljung, Massimo Morfini, Eduardo Remor, Elena Santagostino, Silva Zupančić Šalek

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Although effective therapies for haemophilia have been available for decades, the prevention and treatment of joint disease remain major clinical concerns for all haemophilia patients. Early identification of joint disease is vital to initiate or modify treatment, and prevent arthropathy. However, there remains a need for more sensitive and accurate methods, which may also detect improvement in patient outcome with new therapies or different prophylaxis regimens. These topics were explored at the Ninth Zürich Haemophilia Forum. A summary of our shared views on the limitations of current assessment methods, and the potential advantages of more recently developed tools, is provided. Ultrasonography enables more frequent routine monitoring and the early detection of joint disease. In addition, serological markers may provide suitable biomarkers of early arthropathy. To prevent arthropathy, in our opinion, prophylaxis is key to prevent joint bleeds and subsequent initiation of the 'vicious circle of joint disease'. However, issues remain, including when prophylaxis should be started, stopped, and if it is efficacious for inhibitor patients. Once joint bleeding has occurred, enhanced on-demand treatment should be considered. For more advanced stages of joint disease, the issues regarding the treatment options available are explored. Radiosynovectomy should be performed to treat chronic synovitis, and may prevent the need for elective orthopaedic surgery (EOS). Ultimately, however, EOS can be considered once all other treatment options have been explored. While, bypassing agents have facilitated the use of EOS in inhibitor patients, a multidisciplinary approach and careful surveillance is required for good patient outcome.

Original languageEnglish
Pages (from-to)967-971
Number of pages5
JournalThrombosis Research
Volume133
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

Joint Diseases
Hemophilia A
Orthopedics
Therapeutics
Joints
Synovitis
Early Diagnosis
Ultrasonography
Biomarkers
Hemorrhage

Keywords

  • Arthropathy
  • Haemophilia
  • Inhibitors
  • Joint score
  • On-demand treatment
  • Prophylaxis

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Lambert, T., Auerswald, G., Benson, G., Hedner, U., Jiménez-Yuste, V., Ljung, R., ... Zupančić Šalek, S. (2014). Joint disease, the hallmark of haemophilia: What issues and challenges remain despite the development of effective therapies? Thrombosis Research, 133(6), 967-971. https://doi.org/10.1016/j.thromres.2014.02.015

Joint disease, the hallmark of haemophilia : What issues and challenges remain despite the development of effective therapies? / Lambert, Thierry; Auerswald, Günter; Benson, Gary; Hedner, Ulla; Jiménez-Yuste, Victor; Ljung, Rolf; Morfini, Massimo; Remor, Eduardo; Santagostino, Elena; Zupančić Šalek, Silva.

In: Thrombosis Research, Vol. 133, No. 6, 2014, p. 967-971.

Research output: Contribution to journalArticle

Lambert, T, Auerswald, G, Benson, G, Hedner, U, Jiménez-Yuste, V, Ljung, R, Morfini, M, Remor, E, Santagostino, E & Zupančić Šalek, S 2014, 'Joint disease, the hallmark of haemophilia: What issues and challenges remain despite the development of effective therapies?', Thrombosis Research, vol. 133, no. 6, pp. 967-971. https://doi.org/10.1016/j.thromres.2014.02.015
Lambert, Thierry ; Auerswald, Günter ; Benson, Gary ; Hedner, Ulla ; Jiménez-Yuste, Victor ; Ljung, Rolf ; Morfini, Massimo ; Remor, Eduardo ; Santagostino, Elena ; Zupančić Šalek, Silva. / Joint disease, the hallmark of haemophilia : What issues and challenges remain despite the development of effective therapies?. In: Thrombosis Research. 2014 ; Vol. 133, No. 6. pp. 967-971.
@article{f27d232da1fb4b11ab9c79e7c5b2d393,
title = "Joint disease, the hallmark of haemophilia: What issues and challenges remain despite the development of effective therapies?",
abstract = "Although effective therapies for haemophilia have been available for decades, the prevention and treatment of joint disease remain major clinical concerns for all haemophilia patients. Early identification of joint disease is vital to initiate or modify treatment, and prevent arthropathy. However, there remains a need for more sensitive and accurate methods, which may also detect improvement in patient outcome with new therapies or different prophylaxis regimens. These topics were explored at the Ninth Z{\"u}rich Haemophilia Forum. A summary of our shared views on the limitations of current assessment methods, and the potential advantages of more recently developed tools, is provided. Ultrasonography enables more frequent routine monitoring and the early detection of joint disease. In addition, serological markers may provide suitable biomarkers of early arthropathy. To prevent arthropathy, in our opinion, prophylaxis is key to prevent joint bleeds and subsequent initiation of the 'vicious circle of joint disease'. However, issues remain, including when prophylaxis should be started, stopped, and if it is efficacious for inhibitor patients. Once joint bleeding has occurred, enhanced on-demand treatment should be considered. For more advanced stages of joint disease, the issues regarding the treatment options available are explored. Radiosynovectomy should be performed to treat chronic synovitis, and may prevent the need for elective orthopaedic surgery (EOS). Ultimately, however, EOS can be considered once all other treatment options have been explored. While, bypassing agents have facilitated the use of EOS in inhibitor patients, a multidisciplinary approach and careful surveillance is required for good patient outcome.",
keywords = "Arthropathy, Haemophilia, Inhibitors, Joint score, On-demand treatment, Prophylaxis",
author = "Thierry Lambert and G{\"u}nter Auerswald and Gary Benson and Ulla Hedner and Victor Jim{\'e}nez-Yuste and Rolf Ljung and Massimo Morfini and Eduardo Remor and Elena Santagostino and {Zupančić Šalek}, Silva",
year = "2014",
doi = "10.1016/j.thromres.2014.02.015",
language = "English",
volume = "133",
pages = "967--971",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Joint disease, the hallmark of haemophilia

T2 - What issues and challenges remain despite the development of effective therapies?

AU - Lambert, Thierry

AU - Auerswald, Günter

AU - Benson, Gary

AU - Hedner, Ulla

AU - Jiménez-Yuste, Victor

AU - Ljung, Rolf

AU - Morfini, Massimo

AU - Remor, Eduardo

AU - Santagostino, Elena

AU - Zupančić Šalek, Silva

PY - 2014

Y1 - 2014

N2 - Although effective therapies for haemophilia have been available for decades, the prevention and treatment of joint disease remain major clinical concerns for all haemophilia patients. Early identification of joint disease is vital to initiate or modify treatment, and prevent arthropathy. However, there remains a need for more sensitive and accurate methods, which may also detect improvement in patient outcome with new therapies or different prophylaxis regimens. These topics were explored at the Ninth Zürich Haemophilia Forum. A summary of our shared views on the limitations of current assessment methods, and the potential advantages of more recently developed tools, is provided. Ultrasonography enables more frequent routine monitoring and the early detection of joint disease. In addition, serological markers may provide suitable biomarkers of early arthropathy. To prevent arthropathy, in our opinion, prophylaxis is key to prevent joint bleeds and subsequent initiation of the 'vicious circle of joint disease'. However, issues remain, including when prophylaxis should be started, stopped, and if it is efficacious for inhibitor patients. Once joint bleeding has occurred, enhanced on-demand treatment should be considered. For more advanced stages of joint disease, the issues regarding the treatment options available are explored. Radiosynovectomy should be performed to treat chronic synovitis, and may prevent the need for elective orthopaedic surgery (EOS). Ultimately, however, EOS can be considered once all other treatment options have been explored. While, bypassing agents have facilitated the use of EOS in inhibitor patients, a multidisciplinary approach and careful surveillance is required for good patient outcome.

AB - Although effective therapies for haemophilia have been available for decades, the prevention and treatment of joint disease remain major clinical concerns for all haemophilia patients. Early identification of joint disease is vital to initiate or modify treatment, and prevent arthropathy. However, there remains a need for more sensitive and accurate methods, which may also detect improvement in patient outcome with new therapies or different prophylaxis regimens. These topics were explored at the Ninth Zürich Haemophilia Forum. A summary of our shared views on the limitations of current assessment methods, and the potential advantages of more recently developed tools, is provided. Ultrasonography enables more frequent routine monitoring and the early detection of joint disease. In addition, serological markers may provide suitable biomarkers of early arthropathy. To prevent arthropathy, in our opinion, prophylaxis is key to prevent joint bleeds and subsequent initiation of the 'vicious circle of joint disease'. However, issues remain, including when prophylaxis should be started, stopped, and if it is efficacious for inhibitor patients. Once joint bleeding has occurred, enhanced on-demand treatment should be considered. For more advanced stages of joint disease, the issues regarding the treatment options available are explored. Radiosynovectomy should be performed to treat chronic synovitis, and may prevent the need for elective orthopaedic surgery (EOS). Ultimately, however, EOS can be considered once all other treatment options have been explored. While, bypassing agents have facilitated the use of EOS in inhibitor patients, a multidisciplinary approach and careful surveillance is required for good patient outcome.

KW - Arthropathy

KW - Haemophilia

KW - Inhibitors

KW - Joint score

KW - On-demand treatment

KW - Prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=84900486542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900486542&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2014.02.015

DO - 10.1016/j.thromres.2014.02.015

M3 - Article

C2 - 24613700

AN - SCOPUS:84900486542

VL - 133

SP - 967

EP - 971

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 6

ER -